{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:51Z","timestamp":1791340371893,"version":"4.3.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,12,21]]},"DOI":"10.1007\/s10067-006-0283-5","type":"journal-article","created":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T09:16:25Z","timestamp":1143796585000},"page":"211-215","source":"Crossref","is-referenced-by-count":129,"title":["Comparison of serum IL-1\u03b2, sIL-2R, IL-6, and TNF-\u03b1 levels with disease activity parameters in ankylosing spondylitis"],"prefix":"10.1007","volume":"26","author":[{"given":"A.","family":"Bal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Aydog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Eksioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yorgancioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"283_CR1","first-page":"623","volume-title":"Oxford textbook of rheumatology","author":"RE Banks","year":"1998","unstructured":"Banks RE, Whicher T, Thompson D, Bird HA (1998) Investigation of the rheumatic diseases. In: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds) Oxford textbook of rheumatology. Oxford University Press, New York, pp 623\u2013631"},{"key":"283_CR2","volume-title":"Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis","author":"CA Dinarello","year":"1999","unstructured":"Dinarello CA, Moldawer LL (1999) Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. Amgen, Thousand Oaks, CA"},{"key":"283_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00390264","volume":"13","author":"E Toussirot","year":"1994","unstructured":"Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of IL-1\u03b2, tumor necrosis factor-\u03b1, soluble interleukin 2 receptor and soluble CD8 in seronegative spondyloarthropathies. Rheumatol Int 13:175\u2013180","journal-title":"Rheumatol Int"},{"issue":"5","key":"283_CR4","first-page":"944","volume":"13","author":"EC Keystone","year":"1986","unstructured":"Keystone EC, Jaglal S, Shore A (1986) Interleukin 1 and interleukin 2 generation by peripheral blood cells from patients with ankylosing spondylitis. J Rheumatol 13(5):944\u2013947","journal-title":"J Rheumatol"},{"key":"283_CR5","first-page":"285","volume-title":"Textbook of rheumatology","author":"CA Dinarello","year":"1989","unstructured":"Dinarello CA (1989) Interleukin-1 and other growth factors. In: Kelly WN et al (eds) Textbook of rheumatology, 3rd edn. Saunders, Philadelphia, PA, pp 285\u2013299","edition":"3"},{"key":"283_CR6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2003","unstructured":"Lipsky PE, Van der Heijde DM, St Clair EW et al (2003) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"283_CR7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept theraphy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 130:478\u2013486","journal-title":"Ann Intern Med"},{"issue":"6","key":"283_CR8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665\u2013670","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"283_CR9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/ard.2003.011023","volume":"62","author":"C Keller","year":"2003","unstructured":"Keller C, Webb A, Davis J (2003) Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 62(12):1128\u20131132","journal-title":"Ann Rheum Dis"},{"key":"283_CR10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/rheumatology\/24.3.242","volume":"24","author":"A Goei","year":"1985","unstructured":"Goei A, Steven MM, Sjef M et al (1985) Evaluation of diagnostic criteria for ankylosing spondylitis. A comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 24:242\u2013249","journal-title":"Br J Rheumatol"},{"key":"283_CR11","first-page":"2286","volume":"21","author":"S Garret","year":"1994","unstructured":"Garret S, Jenkinson T et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"283_CR12","first-page":"2281","volume":"21","author":"A Cain","year":"1994","unstructured":"Cain A, Garret S et al (1994) A new approach to defining functional ability in ankylosing spondylitis. The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"283_CR13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/34.8.767","volume":"34","author":"LG Kennedy","year":"1993","unstructured":"Kennedy LG et al (1993) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34:767\u2013770","journal-title":"Br J Rheumatol"},{"issue":"3","key":"283_CR14","first-page":"522","volume":"29","author":"M Vazquez-Del Mercado","year":"2002","unstructured":"Vazquez-Del Mercado M et al (2002) Interleukin 1\u03b2 (IL-1\u03b2), IL-10, tumor necrosis factor-\u03b1 and cellular proliferation index in peripheral blood mononuclear cells in patient with ankylosing spondylitis. J Rheumatol 29(3):522\u2013526","journal-title":"J Rheumatol"},{"issue":"3","key":"283_CR15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00063030-200418030-00006","volume":"18","author":"PL Cormack Mc","year":"2004","unstructured":"Mc Cormack PL, Wellington K (2004) Etanercept: in ankylosing spondylitis. BioDrugs 18(3):199\u2013205 (discussion 206)","journal-title":"BioDrugs"},{"issue":"2","key":"283_CR16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J et al (2005) Open label trial of anakinra in active ankylosing spondylitis over 24\u00a0weeks. Ann Rheum Dis 64(2):296\u2013298","journal-title":"Ann Rheum Dis"},{"key":"283_CR17","first-page":"27","volume":"339","author":"J Gratacos","year":"1994","unstructured":"Gratacos J et al (1994) Serum cytokines (IL-6, TNF-\u03b1, IL-1\u03b2 and IFN-\u03b4) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927\u2013931","journal-title":"Br J Rheumatol"},{"key":"283_CR18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1297-319X(02)00431-1","volume":"69","author":"B Sonel","year":"2002","unstructured":"Sonel B, Tutkak H, Duzgun N (2002) Serum levels of IL-1beta, TNF-alfa, IL-8 and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 69:463\u2013467","journal-title":"Joint Bone Spine"},{"issue":"1","key":"283_CR19","first-page":"1","volume":"20","author":"HC Liu","year":"1987","unstructured":"Liu HC, Hsieh KH (1987) Elevated serum interleukin-2 receptor; increased in vitro immunoglobulin synthesis and lack of response to testosterone-enhanced in vitro interleukin-2 production in ankylosing spondylitis. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 20(1):1\u20138","journal-title":"Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi"},{"key":"283_CR20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.53.6.425-b","volume":"53","author":"ZN Tutuncu","year":"1994","unstructured":"Tutuncu ZN et al (1994) Interleukin-6 acute phases reactance and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425\u2013428","journal-title":"Ann Rheum Dis"},{"key":"283_CR21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/rheumatology\/36.3.400","volume":"37","author":"P Claudepierre","year":"1997","unstructured":"Claudepierre P, Rymer J-C, Authier F-J et al (1997) A relationship between TGF-\u03b21 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 37:400\u2013406","journal-title":"Br J Rheumatol"},{"key":"283_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002960050066","volume":"18","author":"A Falkenbach","year":"1998","unstructured":"Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103\u2013106","journal-title":"Rheumatol Int"},{"key":"283_CR23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.copbio.2004.09.005","volume":"15","author":"PC Taylor","year":"2004","unstructured":"Taylor PC, Williams RO, Feldman M (2004) Tumour necrosis factor \u03b1 as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 15:557\u2013563","journal-title":"Curr Opin Biotechnol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-006-0283-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0283-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:50:59Z","timestamp":1559105459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-006-0283-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,12,21]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1007\/s10067-006-0283-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}